News | May 12, 2025
Jagsonpal Pharmaceuticals posts Q4 FY25 PAT at Rs. 6.58 Cr
The company has posted net profit of Rs. 55.36 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 55.36 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 582.01 crores for the Financial Year ended March 31, 2025
RPG Life Sciences has reported total income of Rs. 148.15 crores during the period ended March 31, 2025
Vimta Labs has reported total income of Rs. 96.08 crores during the period ended March 31, 2025
The company has posted net profit of Rs. 406.7 crores for the Financial Year ended March 31, 2025
The company has reported total income of Rs. 628.4 crores during the period ended March 31, 2025
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience
Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease
During the quarter, the company posted Revenue from operations at Rs. 5,269 crore as compared to Rs. 4,505 crore in Q3 FY25, posting a growth of 17 per cent
Subscribe To Our Newsletter & Stay Updated
